Sugi Predict

Sugi Predict / Compounds / SCHEMBL994780

SCHEMBL994780

SCHEMBL994780

O=C1C=c2c(ccc3ccccc23)=CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PAX8 Q06710 1/20 0.38
▸ HSD17B10 Q99714 3/20 0.38
▸ CYP2A6 P11509 2/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ TSHR P16473 1/20 0.38
▸ HPRT1 P00492 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ CYP1A2 P05177 2/20 0.33
▸ DNMT1 P26358 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ SIRT1 Q96EB6 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ CYP1B1 Q16678 1/20 0.33
▸ CES1 P23141 1/20 0.33
▸ PARP1 P09874 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL25188851 0.98 PAX8 (0.37) PAX8HSD17B10CYP2A6TDP1ALDH1A1
SCHEMBL3287319 0.86 PAX8 (0.38) PAX8HSD17B10CYP2A6TDP1ALDH1A1
SCHEMBL3384886 0.78 HPRT1 (0.45) PAX8HSD17B10CYP2A6TDP1ALDH1A1
SCHEMBL11504266 0.76 HPRT1 (0.45) PAX8HSD17B10CYP2A6TDP1ALDH1A1
SCHEMBL23840 0.75 ALDH1A1 (0.47) PAX8HSD17B10CYP2A6TDP1ALDH1A1
SCHEMBL5313840 0.75 ALDH1A1 (0.47) PAX8HSD17B10CYP2A6TDP1ALDH1A1
SCHEMBL30174123 0.75 ALDH1A1 (0.34) HSD17B10CYP2A6TDP1ALDH1A1TSHR
SCHEMBL2479044 0.73 CYP2A6 (0.44) PAX8HSD17B10CYP2A6TDP1ALDH1A1
SCHEMBL21805847 0.73 ALDH1A1 (0.44) PAX8HSD17B10CYP2A6TDP1ALDH1A1
SCHEMBL8661052 0.71 CYP2A6 (0.46) PAX8HSD17B10CYP2A6TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110198949-B Process for the preparation of 9 beta, 10 alpha-progesterone (retroprogesterone) 工业化学有限公司 2022-05-10 — — CN claimed
EP-2527345-B1 Therapeutic pyrazolyl thienopyridines THESAN PHARMACEUTICALS INC (US) 2015-12-16 — — EP claimed
EP-2688570-B1 6-SUBSTITUTED ESTRADIOL DERIVATIVES FOR USE IN REMYELINATION OF NERVE AXONS ENDECE LLC (US) 2015-11-18 — — EP claimed
WO-2014089904-A1 TRIAZINONE COMPOUNDS ABBVIE INC. (US) 2014-06-19 — — WO claimed
EP-2507253-A2 6-SUBSTITUTED ESTRADIOL DERIVATIVES AND METHODS OF USE Endece, LLC (US) 2012-10-10 — — EP claimed
WO-2011066542-A2 6-SUBSTITUTED ESTRADIOL DERIVATIVES AND METHODS OF USE ENDECE INC. (US) 2011-06-03 — — WO claimed
US-20260083755-A1 TESTOSTERONE CONTAINING PHARMACEUTICAL COMPOSITION Neurocrine UK Limited (GB) 2026-03-26 — — US disclosed
CN-120152967-A Bifunctional compounds containing 2, 5-substituted pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway 霖康疗法公司 2025-06-13 — — CN disclosed
CN-119816313-A Method of administering natural killer cells containing anti-human epidermal growth factor receptor 2 (HER 2) Chimeric Antigen Receptor (CAR) 埃迪瓦生物治疗公司 2025-04-11 — — CN disclosed
CN-119790053-A Sulfonamide derivatives as cyclin dependent kinase 2 inhibitors 霖康疗法公司 2025-04-08 — — CN disclosed
CN-119744180-A Human tumor necrosis factor alpha antibody glucocorticoid conjugate 伊莱利利公司 2025-04-01 — — CN disclosed
CN-119698436-A Human CD33 antibodies and glucocorticoid conjugates 伊莱利利公司 2025-03-25 — — CN disclosed
CN-119630429-A Human interleukin-4 receptor alpha antibody glucocorticoid conjugates 伊莱利利公司 2025-03-14 — — CN disclosed
WO-2011032984-A1 LUBIPROSTONE FOR OBSTETRICAL OR GYNECOLOGICAL APPLICATIONS ULMANN ANDRE (FR) 2011-03-24 — — WO disclosed
WO-2011009534-A2 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR TREATING DISEASES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-01-27 — — WO disclosed
EP-2238252-A1 MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE GLUTAMINYL CYCLASE GENE Probiodrug AG (DE) 2010-10-13 — — EP disclosed
WO-2009090190-A9 MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE GLUTAMINYL CYCLASE GENE PROBIODRUG AG (DE) 2010-08-26 — — WO disclosed
WO-2009090190-A1 MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE GLUTAMINYL CYCLASE GENE PROBIODRUG AG (DE) 2009-07-23 — — WO disclosed
EP-1399406-B1 NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS I KAROBIO AB (SE) 2005-08-10 — — EP disclosed
WO-2002053522-A2 NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS I KARO BIO AB (SE) 2002-07-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083755-A1 TESTOSTERONE CONTAINING PHARMACEUTICAL COMPOSITION SHBG, TES, CYP17A1 PAX8 2004/4885HSD17B10 31/4885CYP2A6 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.